ADEF
ACTU

ABS Direct Equity Fund’s Actuate Therapeutics ACTU Stock Holding History

ABS Direct Equity Fund’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Buy
73,186
+23,186
+46% +$53.7K 0.07% 108
2026
Q1 		$137K Buy
50,000
+43,403
+658% +$180K 0.1% 98
2025
Q4 		$40.4K Buy
+6,597
New +$45.3K 0.05% 36

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ABS Investment Management Greenwich, Connecticut $159M AUM

ABS Direct Equity Fund's ACTU Position: Q2 2026 in Review

ABS Direct Equity Fund increased its Actuate Therapeutics (ACTU) stake by 46% in Q2 2026, buying an estimated $53.7K and bringing the position to 73,186 shares worth $112K. The position accounts for 0.07% of the portfolio, ranked #108.

ABS Direct Equity Fund first reported a position in ACTU in Q4 2025 and has held it in 3 quarters since. The position peaked at $137K in Q1 2026. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • ABS Direct Equity Fund held 73,186 shares of Actuate Therapeutics worth $112K as of Q2 2026.
  • ABS Direct Equity Fund bought 23,186 Actuate Therapeutics shares in Q2 2026, an estimated $53.7K.
  • Actuate Therapeutics made up 0.07% of ABS Direct Equity Fund's portfolio in Q2 2026, its #108 holding.
  • ABS Direct Equity Fund first reported a position in Actuate Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • ABS Direct Equity Fund's Actuate Therapeutics position peaked at $137K in Q1 2026.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on ABS Direct Equity Fund's 13F filing for Q2 2026, filed 13 Aug 2026.